AQR Capital Management LLC Takes Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

AQR Capital Management LLC purchased a new stake in RAPT Therapeutics, Inc. (NASDAQ:RAPTFree Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 88,373 shares of the company’s stock, valued at approximately $270,000. AQR Capital Management LLC owned 0.25% of RAPT Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Acadian Asset Management LLC purchased a new stake in shares of RAPT Therapeutics in the 1st quarter worth $97,000. EntryPoint Capital LLC bought a new position in RAPT Therapeutics during the 1st quarter worth about $161,000. Denali Advisors LLC purchased a new position in RAPT Therapeutics during the 1st quarter valued at about $293,000. XTX Topco Ltd bought a new stake in shares of RAPT Therapeutics in the 2nd quarter valued at about $108,000. Finally, Hennion & Walsh Asset Management Inc. lifted its position in shares of RAPT Therapeutics by 8.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock worth $148,000 after purchasing an additional 3,824 shares during the period. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Stock Down 3.4 %

Shares of RAPT Therapeutics stock opened at $1.69 on Friday. The company has a 50 day moving average price of $2.03 and a 200 day moving average price of $3.90. The firm has a market capitalization of $58.99 million, a P/E ratio of -0.55 and a beta of 0.33. RAPT Therapeutics, Inc. has a 52 week low of $1.66 and a 52 week high of $27.35.

RAPT Therapeutics (NASDAQ:RAPTGet Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.03. As a group, research analysts anticipate that RAPT Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a report on Tuesday, August 20th. UBS Group cut their price target on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a report on Monday, September 9th. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, RAPT Therapeutics has an average rating of “Hold” and an average target price of $18.17.

Check Out Our Latest Stock Analysis on RAPT

About RAPT Therapeutics

(Free Report)

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Further Reading

Institutional Ownership by Quarter for RAPT Therapeutics (NASDAQ:RAPT)

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.